keyword
MENU ▼
Read by QxMD icon Read
search

Goserelin

keyword
https://www.readbyqxmd.com/read/29786828/oral-contraceptives-for-pain-associated-with-endometriosis
#1
REVIEW
Julie Brown, Tineke J Crawford, Shree Datta, Andrew Prentice
BACKGROUND: Endometriosis is a common gynaecological condition which affects many women of reproductive age worldwide and is a major cause of pain and infertility. The combined oral contraceptive pill (COCP) is widely used to treat pain occurring as a result of endometriosis, although the evidence for its efficacy is limited. OBJECTIVES: To determine the effectiveness, safety and cost-effectiveness of oral contraceptive preparations in the treatment of painful symptoms ascribed to the diagnosis of laparoscopically proven endometriosis...
May 22, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29774129/combined-abiraterone-acetate-plus-prednisone-salvage-prostate-bed-radiotherapy-and-lh-rh-agonists-carlha-gep12-in-biochemically-relapsing-prostate-cancer-patients-following-prostatectomy-a-phase-i-study-of-the-getug-gep
#2
Stéphane Supiot, Loic Campion, Pascal Pommier, Mélanie Dore, Clément Palpacuer, Séverine Racadot, Emmanuel Rio, Gérard A Milano, Céline Mahier-Ait Oukhatar, Christian Carrie
Background: To establish the maximum tolerated dose of abiraterone acetate plus prednisone (AA) combined with salvage radiotherapy (SRT) and goserelin in a phase 1 study in men with rising PSA following radical prostatectomy. Methods: AA was given during one month before SRT at 1000 mg PO once daily, then 750 mg (Dose Level 1, DL1) or 1000 mg (DL2) during 5 months combined with 6-months goserelin by injection on the first day of irradiation (scheme NEO) or one month before starting SRT (scheme CONCO)...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29765254/stump-a-surprise-finding-in-a-large-fibroid-uterus-in-a-20-year-old-woman
#3
Lara Hughes, Alphonse Roex, Anupam Parange
We report on a case of a 20-year-old nulliparous woman with menorrhagia associated with a smooth muscle tumor of uncertain malignant potential (STUMP) that was responsive to Goserelin. This case details the investigation and management of a young woman who desires ongoing fertility preservation. STUMP is a rare uterine tumor with a paucity of literature available regarding management and subsequent malignant potential, particularly in the case of a patient who desires fertility preservation.
2018: International Journal of Women's Health
https://www.readbyqxmd.com/read/29727544/-clinical-efficacy-of-integrated-traditional-chinese-and-western-medicine-for-castration-resistant-prostate-cancer
#4
Yang Zhang, Bo-Han Lei, Qing Zou, Qing-Yi Zhu, Zi-Jie Lu, Yue Wang
Objective: To investigate the clinical effects of integrated traditional Chinese and Western medicine in the treatment of castration-resistant prostate cancer (CRPC). METHODS: A total of 54 CRPC patients were randomly divided into a control and a trial group, all treated by endocrine therapy (oral Bicalutamide at 50 mg per d plus subcutaneous injection of Goserelin at 3.6 mg once every 4 wk) and chemotherapy (intravenous injection of Docetaxel at 75 mg/m2 once every 3 wk plus oral Prednisone at 5 mg bid), while the latter group by Fuyang Huayu Prescription (a Traditional Chinese Medicine [TCM] prescription for tonifying yang and dispersing blood stasis) in addition, for a course of 24 weeks...
October 2017: Zhonghua Nan Ke Xue, National Journal of Andrology
https://www.readbyqxmd.com/read/29624800/efficacy-and-safety-of-3-month-dosing-regimen-of-degarelix-in-japanese-subjects-with-prostate-cancer-a-phase-iii-study
#5
Seiichiro Ozono, Taiji Tsukamoto, Seiji Naito, Shigeo Horie, Yasuo Ohashi, Hiroji Uemura, Yumiko Yokomizo, Satoshi Fukasawa, Hidehito Kusuoka, Rio Akazawa, Masako Saito, Hideyuki Akaza
Non-inferiority in the cumulative castration rate of the 3-month formulation of degarelix compared with the 3-month formulation of goserelin was evaluated in subjects with prostate cancer. A phase III, open-label, parallel-arm study was conducted. An initial dose of 240 mg of degarelix or 3.6 mg of goserelin was subcutaneously administered; after day 28, a maintenance dose of 480 mg of degarelix or 10.8 mg of goserelin was administered once every 84 days. Non-inferiority in castration rate and safety of degarelix to goserelin were evaluated...
April 6, 2018: Cancer Science
https://www.readbyqxmd.com/read/29624463/phase-iii-intergroup-trial-of-adjuvant-androgen-deprivation-with-or-without-mitoxantrone-plus-prednisone-in-patients-with-high-risk-prostate-cancer-after-radical-prostatectomy-swog-s9921
#6
Maha Hussain, Catherine M Tangen, Ian M Thompson, Gregory P Swanson, David P Wood, Wael Sakr, Nancy A Dawson, Naomi B Haas, Thomas W Flaig, Tanya B Dorff, Daniel W Lin, E David Crawford, David I Quinn, Nicholas J Vogelzang, L Michael Glode
Purpose Patients with high-risk prostate cancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and prednisone (MP) to adjuvant ADT could reduce mortality compared with adjuvant ADT alone. Methods Eligible patients had cT1-3N0 prostate cancer with one or more high-risk factors after radical prostatectomy (Gleason score [GS] ≥ 8; pT3b, pT4, or pN+ disease; GS 7 and positive margins; or preoperative prostate-specific antigen [PSA] > 15 ng/mL, biopsy GS score > 7, or PSA > 10 ng/mL plus biopsy GS > 6...
April 6, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29549134/successful-treatment-of-concomitant-metastatic-prostate-cancer-and-b-cell-non-hodgkin-s-lymphoma-with-r-epoch-chemotherapy-regimen-and-antiandrogen-therapy
#7
Fayez Hanna, Ajay Prakash, Ebony Allan, Alhossain A Khalafallah
A 70-year-old man presented with left loin pain without urinary symptoms. Initial investigations with CT showed enlarged para-aortic, mediastinal lymph nodes, right-side renal mass and enlarged prostate. A prostatic-specific antigen (PSA) was alarmingly high at 4750 μg/L (normal <4.0 μg/L). Further investigations included positron emission tomography (PET); both prostate-specific membrane antigen and 18-fluorodeoxyglucose as well as bone scan and bone marrow examination confirmed dual malignancies with B-cell non-Hodgkin's lymphoma (B-NHL) and wide spread metastatic prostatic adenocarcinoma (PA) to the skull, spine, pelvis, liver and lungs...
March 16, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29482885/interleukin-6-and-interleukin-8-serum-levels-in-prognosis-of-hormone-dependent-breast-cancer
#8
Jelena Milovanović, Nataša Todorović-Raković, Marko Radulovic
BACKGROUND: Increasing amount of evidence points to the importance of immunity in breast cancer. The prognostic value of cytokines and their effect on tumorigenesis remains inconsistent. AIM: To investigate the prognostic significance of IL6 and IL8 and their association with ER and HER2 in estrogen-dependent (ER+) breast cancer. MATERIAL AND METHODS: The study included 79 premenopausal women with early and locally advanced ER+ breast cancer...
February 23, 2018: Cytokine
https://www.readbyqxmd.com/read/29450591/occurrence-of-pneumonitis-following-radiotherapy-of-breast-cancer-a-prospective-study
#9
Danijela Vasiljevic, Christoph Arnold, David Neuman, Katharina Fink, Marina Popovscaia, Irma Kvitsaridze, Meinhard Nevinny-Stickel, Markus Glatzer, Peter Lukas, Thomas Seppi
AIM: of this study is to determine the temporal resolution of therapy-induced pneumonitis, and to assess promoting factors in adjuvant treated patients with unilateral mammacarcinoma. PATIENTS AND METHODS: A total of 100 post-surgery patients were recruited. The cohort was treated by 2 field radiotherapy (2FRT; breast and chest wall, N = 75), 3 field radiotherapy (3FRT; + supraclavicular lymphatic region, N = 8), or with 4 field radiotherapy (4FRT; + parasternal lymphatic region, N = 17)...
February 15, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29438592/are-all-gonadotropin-releasing-hormone-agonists-equivalent-for-the-treatment-of-prostate-cancer-a-systematic-review
#10
REVIEW
Eva M Bolton, Thomas H Lynch
OBJECTIVES: To review comparative studies of the gonadotropin-releasing hormone (GnRH) agonists goserelin, triptorelin, and leuprorelin for the treatment of prostate cancer, and identify whether there are meaningful clinical differences between these agents. METHODS: In June 2017, the following searches were performed independently by two reviewers in PubMed: (i) 'prostate cancer' and 'triptorelin' and 'leuprorelin', (ii) 'prostate cancer' and 'triptorelin' and 'goserelin', and (iii) 'prostate cancer' and 'goserelin' and 'leuprorelin', without time restriction...
February 13, 2018: BJU International
https://www.readbyqxmd.com/read/29434673/practical-differences-between-luteinizing-hormone-releasing-hormone-agonists-in-prostate-cancer-perspectives-across-the-spectrum-of-care
#11
REVIEW
Davide Meani, Mladen Solarić, Harri Visapää, Rose-Marie Rosén, Robert Janknegt, Majana Soče
Background: Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists is well established for the treatment of men with metastatic prostate cancer. As clear differences in efficacy, safety, or tolerability between the available LHRH agonists are lacking, the healthcare management team needs to look to practical differences between the formulations when selecting therapy for their patients. Moreover, as the economic burden of prostate cancer rises alongside earlier diagnosis and improved survival, the possibility for cost savings by using products with specific features is growing in importance...
February 2018: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29383406/use-of-androgen-deprivation-and-salvage-radiation-therapy-for-patients-with-prostate-cancer-and-biochemical-recurrence-after-prostatectomy
#12
Pirus Ghadjar, Daniel M Aebersold, Clemens Albrecht, Dirk Böhmer, Michael Flentje, Ute Ganswindt, Stefan Höcht, Tobias Hölscher, Felix Sedlmayer, Frederik Wenz, Daniel Zips, Thomas Wiegel
AIM: Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. METHODS: The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published between January 2009 and May 2017, and assessed the validity of the information on outcome parameters including overall survival (OS) and treatment-related toxicity. RESULTS: Two randomized controlled trials and nine relevant retrospective analyses were identified...
January 30, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29377270/frontal-fibrosing-alopecia-after-antiandrogen-hormonal-therapy-in-a-male-patient
#13
LETTER
A Lobato-Berezo, A March-Rodríguez, G Deza, M Bertolín-Colilla, R M Pujol
No abstract text is available yet for this article.
January 29, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29357022/impact-on-disease-free-survival-of-the-duration-of-ovarian-function-suppression-as-postoperative-adjuvant-therapy-in-premenopausal-women-with-hormone-receptor-positive-breast-cancer-a-retrospective-single-institution-study
#14
Yukinori Ozaki, Yuko Tanabe, Nobuko Tamura, Takuya Ogura, Chihiro Kondoh, Yuji Miura, Kenichi Yoshimura, Hidetaka Kawabata, Toshimi Takano
INTRODUCTION: Although tamoxifen (TAM) plus ovarian function suppression (OFS) is considered as a standard adjuvant treatment for premenopausal women with hormone receptor-positive breast cancer, the optimal duration of OFS has not yet been established. This retrospective study was designed to assess the duration of OFS and the impact of the duration of OFS on the DFS in these patients. METHODS: We retrospectively reviewed the data of premenopausal patients with breast cancer who received TAM + OFS (goserelin or leuprorelin) as adjuvant therapy between February 2004 and June 2015...
May 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29337395/testosterone-suppression-with-luteinizing-hormone-releasing-hormone-lhrh-agonists-in-patients-receiving-radiotherapy-for-prostate-cancer
#15
Derek Wilke, Nikhilesh Patil, Helmut Hollenhorst, David Bowes, Robert Rutledge, Casely Ago
OBJECTIVES: To characterize the probability of testosterone escape during a course of radiotherapy and androgen deprivation (ADT) in patients with prostate cancer, and examine predictors of testosterone escape, the prostate specific antigen (PSA) levels during testosterone escape, and the impact of testosterone escape on outcome. PATIENTS AND METHODS: To participate in the database review, necessary data included: (i) type of luteinizing hormone-releasing hormone agonist (LHRHa) administered, date of initiation, and date of cessation or duration of therapy, (ii) radiotherapy information (start date and dose) with at least 6 months of follow-up after radiotherapy, (iii) radiotherapy to the prostate or prostate bed, and (iv) at least one serum testosterone and PSA measurement...
March 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29286125/goserelin-promotes-the-apoptosis-of-epithelial-ovarian-cancer-cells-by-upregulating-forkhead-box-o1-through-the-pi3k-akt-signaling-pathway
#16
Ning Zhang, Junjun Qiu, Tingting Zheng, Xiaodan Zhang, Keqin Hua, Ying Zhang
Gonadotropins, including luteinizing hormone (LH) and follicle stimulating hormone (FSH), are conducive to the growth of ovarian cancer based on the 'gonadotropin theory' and are regulated by gonadotropin-releasing hormone (GnRH). The present study was carried out to investigate the effect of goserelin, a GnRH agonist, on the apoptosis of epithelial ovarian cancer (EOC) cells and the underlying in vitro and in vivo mechanisms. Through flow cytometry, Hoechst staining and TUNEL staining, we demonstrated that goserelin promoted the apoptosis of EOC cells both in vitro and in vivo...
March 2018: Oncology Reports
https://www.readbyqxmd.com/read/29273727/radiosensitization-of-prostate-cancers-in-vitro-and-in-vivo-to-erbium-filtered-orthovoltage-x-rays-using-actively-targeted-gold-nanoparticles
#17
Allison M Khoo, Sang Hyun Cho, Francisco J Reynoso, Maureen Aliru, Kathryn Aziz, Monica Bodd, Xi Yang, Md F Ahmed, Selcuk Yasar, Nivedh Manohar, Jongmin Cho, Ramesh Tailor, Howard D Thames, Sunil Krishnan
Theoretical investigations suggest that gold nanoparticle (GNP)-mediated radiation dose enhancement and radiosensitization can be maximized when photons interact with gold, predominantly via photoelectric absorption. This makes ytterbium (Yb)-169, which emits photons with an average energy of 93 keV (just above the K-edge of gold), an ideal radioisotope for such purposes. This investigation tests the feasibility of tumor-specific prostate brachytherapy achievable with Yb-169 and actively targeted GNPs, using an external beam surrogate of Yb-169 created from an exotic filter material - erbium (Er) and a standard copper-filtered 250 kVp beam...
December 22, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29187457/transdermal-delivery-of-luteinizing-hormone-releasing-hormone-with-chitosan-microneedles-a-promising-tool-for-androgen-deprivation-therapy
#18
Ming-Yang Chen, Yi-Ying Chen, Hsin-Tzu Tsai, Tzong-Shin Tzai, Mei-Chin Chen, Yuh-Shyan Tsai
Long-term administration of luteinizing hormone-releasing hormone analogs (LHRHa) is the main type of androgen-deprivation therapy (ADT) for lethal prostate cancer. A fully insertable microneedle system, composed of embeddable chitosan microneedles and a dissolvable polyvinyl alcohol/polyvinyl pyrrolidone supporting array, was developed for sustained delivery of LHRHa to the skin. A porcine cadaver skin test showed that chitosan microneedles can be fully embedded within the skin and microneedle-created micropores reseal within 7 days...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29117576/the-utility-of-anti-m%C3%A3-llerian-hormone-in-the-diagnosis-and-prediction-of-loss-of-ovarian-function-following-chemotherapy-for-early-breast-cancer
#19
RANDOMIZED CONTROLLED TRIAL
R A Anderson, J Mansi, R E Coleman, D J A Adamson, R C F Leonard
AIM: Chemotherapy results in permanent loss of ovarian function in some premenopausal women. Accurate identification in women with hormone-sensitive early breast cancer (eBC) would allow optimisation of subsequent endocrine treatment. We sought to assess whether analysis of anti-Müllerian hormone (AMH) using a sensitive automated assay could identify women who would not regain ovarian function after chemotherapy. METHODS: Data from women in the Ovarian Protection Trial in Premenopausal Breast Cancer Patients (OPTION) trial of goserelin (a gonadotrophin-releasing hormone (GnRH) analogue) for ovarian protection were analysed...
December 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29112733/goserelin-does-not-preserve-ovarian-function-against-chemotherapy-induced-damage
#20
K Oktay, E Taylan, K A Rodriguez-Wallberg, G Bedoschi, V Turan, F Pacheco
No abstract text is available yet for this article.
February 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
36607
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"